Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
KRON.US
id: 1605

Kronos Bio ($KRON) Misleading Merger Proxy and Insider Enrichment Case

Investors can submit applications for the lead plaintiff role.
N.D. California
Court
3:25-cv-04322
Case number
05/01/2025
Class period Start
07/21/2025
Lead Plaintiff motion deadline
  • $KRON investors filed a claim against Kronos Bio for misleading disclosures tied to its merger with Concentra and failing to share key financial information.
  • The case challenges the fairness of the $0.57-per-share tender offer and alleges that executives prioritized personal payouts over shareholder value.
  • $KRON investors can join this case to be notified about potential recovery.
Case Details:

On May 1, 2025, Kronos Bio announced it had agreed to be acquired by Concentra Biosciences for $0.57 per share in cash, plus a non-tradeable contingent value right (CVR) tied to the sale of its remaining drug candidates. Kronos filed a recommendation statement urging shareholders to tender their shares.

But the proxy lacked critical information. It did not include the financial projections Kronos shared with other bidders during the sales process, nor did it disclose how different confidentiality agreements may have influenced who could bid. The company also omitted details about potential post-merger employment negotiations that may have swayed board members.

The proxy further failed to fully explain the valuation assumptions behind Leerink’s fairness opinion, including key inputs used to calculate dissolution values. Meanwhile, top executives and directors stood to gain millions in merger-related payouts and golden parachutes—compensation that public shareholders would not receive.

Based on these events, $KRON investors filed a claim against Kronos Bio and its board, accusing them of the following:
  • It misled shareholders by omitting critical financial projections and deal background from the merger proxy.
  • It failed to disclose insider conflicts, including potential job offers and disproportionate payouts.
Considering all the representations, investors believe the Kronos board prioritized personal gain over securing full value for shareholders.
Case Type
US Securities Class Action
Case Status
Lead Plaintiff Submission
Alleged Offence
Misleading Statements
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
05/01/2025
Filing date
05/20/2025
Lead Plaintiff Deadline
07/21/2025

Kronos Bio Inc

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States...

    Ticker
    KRON.US
    ISIN
    US50107A1043
    CIK
    0001741830
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    1300 So. El Camino Real, San Mateo, CA, United States, 94402